{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266866","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.454689+00:00","generated_at":"2026-05-17T00:21:31.220114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcellx Q3 2025 net loss widens to $55.8M; collaboration revenue drops 81%","bullets":["Cash, equivalents, and marketable securities of $576.0M as of Sep 30, 2025; expected to fund operations into 2028.","Collaboration revenue fell to $4.9M from $26.0M YoY, driven by completion of anito-cel dosing in iMMagine-1 trial.","R&D expenses decreased to $35.1M from $39.2M YoY; G&A expenses rose to $31.6M from $20.5M YoY on commercial readiness costs.","Net loss was $55.8M compared to $25.9M in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266866","json":"https://secwatch.observer/filing/0001193125-25-266866.json","markdown":"https://secwatch.observer/filing/0001193125-25-266866.md","text":"https://secwatch.observer/filing/0001193125-25-266866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525266866/0001193125-25-266866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525266866/aclx-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:21:31.220114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}